Positive News SentimentPositive News AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX) $0.83 +0.07 (+9.21%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$0.75▼$0.8450-Day Range$0.46▼$0.8352-Week Range$0.43▼$2.78Volume79,693 shsAverage Volume206,114 shsMarket Capitalization$14.07 millionP/E RatioN/ADividend YieldN/APrice Target$4.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability AcelRx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside457.2% Upside$4.63 Price TargetShort InterestHealthy4.68% of Float Sold ShortDividend StrengthN/ASustainability-2.41Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$8,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.40) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector125th out of 952 stocksPharmaceutical Preparations Industry42nd out of 434 stocks 3.5 Analyst's Opinion Consensus RatingAcelRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.63, AcelRx Pharmaceuticals has a forecasted upside of 457.2% from its current price of $0.83.Amount of Analyst CoverageAcelRx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.68% of the float of AcelRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcelRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AcelRx Pharmaceuticals has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcelRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcelRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for AcelRx Pharmaceuticals is -2.41. Previous Next 3.8 News and Social Media Coverage News SentimentAcelRx Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.Search Interest22 people have searched for ACRX on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows3 people have added AcelRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AcelRx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of AcelRx Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 19.79% of the stock of AcelRx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AcelRx Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AcelRx Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcelRx Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Read More ACRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRX Stock News HeadlinesNovember 25, 2023 | americanbankingnews.comAcelRx Pharmaceuticals (NASDAQ:ACRX) Receives New Coverage from Analysts at StockNews.comNovember 22, 2023 | msn.comAcelRx Pharmaceuticals files for $150M mixed shelfDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 7, 2023 | msn.comAcelRx Pharmaceuticals Q3 2023 Earnings PreviewNovember 7, 2023 | finance.yahoo.comAcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyOctober 26, 2023 | finance.yahoo.comAcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023October 3, 2023 | finance.yahoo.comAcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudyDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. September 12, 2023 | msn.comAcelRx CEO buys 10,000 sharesSeptember 12, 2023 | finance.yahoo.comInsider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals IncAugust 22, 2023 | finance.yahoo.comWhat Makes AcelRx Pharmaceuticals (ACRX) a New Buy StockAugust 18, 2023 | markets.businessinsider.comPositive Report for Acelrx (ACRX) from H.C. WainwrightAugust 13, 2023 | finance.yahoo.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call TranscriptAugust 12, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comQ2 2023 AcelRx Pharmaceuticals Inc Earnings CallAugust 11, 2023 | finance.yahoo.comAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comAcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue EstimatesJuly 28, 2023 | finance.yahoo.comAcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023July 21, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq RulesJuly 18, 2023 | seekingalpha.comAcelRx Pharmaceuticals launches ~$10M private placement of sharesJuly 18, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesJune 17, 2023 | finance.yahoo.comACRX - AcelRx Pharmaceuticals, Inc.June 16, 2023 | fool.comAcelRx Pharmaceuticals (NASDAQ: ACRX)May 13, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | msn.comRecap: AcelRx Pharmaceuticals Q1 EarningsMay 10, 2023 | finance.yahoo.comAcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1See More Headlines Receive ACRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRX CUSIPN/A CIK1427925 Webwww.acelrx.com Phone(650) 216-3500Fax650-216-6500Employees19Year FoundedN/APrice Target and Rating Average Stock Price Target$4.63 High Stock Price Target$5.00 Low Stock Price Target$4.25 Potential Upside/Downside+457.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$47.76 million Net MarginsN/A Pretax Margin-3,711.25% Return on Equity-81.54% Return on Assets-46.02% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$1.77 million Price / Sales7.95 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book0.31Miscellaneous Outstanding Shares16,950,000Free Float16,443,000Market Cap$14.07 million OptionableOptionable Beta0.64 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Vincent J. Angotti (Age 55)CEO & Director Comp: $906.54kDr. Pamela Pierce Palmer M.D. (Age 60)Ph.D., Co-Founder, Chief Medical Officer & Director Comp: $699.75kMr. Raffi Mark Asadorian (Age 54)Chief Financial Officer Comp: $637.5kMr. Anil N. Dasu (Age 60)Chief Engineering Officer Comp: $478.09kKey CompetitorsGeoVax LabsNASDAQ:GOVXMustang BioNASDAQ:MBIOCNS PharmaceuticalsNASDAQ:CNSPBionomicsNASDAQ:BNOXContext TherapeuticsNASDAQ:CNTXView All CompetitorsInsiders & InstitutionsCowen AND Company LLCBought 115,657 shares on 11/9/2023Ownership: 0.708%Vincent J AngottiBought 10,000 shares on 9/11/2023Total: $8,000.00 ($0.80/share)Pamela P PalmerSold 9,514 sharesTotal: $11,131.38 ($1.17/share)View All Insider TransactionsView All Institutional Transactions ACRX Stock Analysis - Frequently Asked Questions Should I buy or sell AcelRx Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRX shares. View ACRX analyst ratings or view top-rated stocks. What is AcelRx Pharmaceuticals' stock price target for 2024? 2 equities research analysts have issued 12 month target prices for AcelRx Pharmaceuticals' shares. Their ACRX share price targets range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next year. This suggests a possible upside of 457.2% from the stock's current price. View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts. How have ACRX shares performed in 2023? AcelRx Pharmaceuticals' stock was trading at $2.26 on January 1st, 2023. Since then, ACRX stock has decreased by 63.3% and is now trading at $0.83. View the best growth stocks for 2023 here. When is AcelRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ACRX earnings forecast. How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The specialty pharmaceutical company had revenue of $0.12 million for the quarter. When did AcelRx Pharmaceuticals' stock split? AcelRx Pharmaceuticals shares reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA). Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (0.71%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti. View institutional ownership trends. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACRX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.